- Real-world patients with type 2 diabetes (T2D) would be most likely to meet enrollment criteria for DECLARE-TIMI 58 compared with 3 other trials of cardiovascular outcomes.
- This finding implies that dapagliflozin should be considered as the sodium-glucose co-transporter-2 inhibitor (SGLT2i) with the greatest generalizability potential among such trials.
Why this matters
- Evaluating eligibility for these trials informs clinical practice.
- Evidence from these trials of cardiovascular outcomes overall supports SGLT2i use in patients with T2D and a history of cardiovascular disease or risk factors.
- Up to only 1 in 5 patients would meet enrollment criteria for these clinical trials.
- Meta-analysis of 5 cardiovascular outcome trials; n=1,703,519.
- Funding: None.
- Prevalence of eligible patients in analytic cohorts according to enrollment criteria:
- In head-to-head comparisons of prevalence of eligibility, odds of meeting enrollment criteria:
- DECLARE-TIMI 58 vs CANVAS: 1.74 (P=.003).
- DECLARE-TIMI 58 vs EMPA-REG OUTCOME: 5.15 (P<.001>
- DECLARE-TIMI 58 vs VERTIS-CV: 4.81 (P<.001>
- Limited number of studies, countries.
- Heterogeneity for all endpoints, reporting of baseline characteristics.
- Some baseline characteristics not reported.